Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan;55(1):26-48.
doi: 10.1111/apt.16656. Epub 2021 Nov 9.

Systematic review: the association between the gut microbiota and medical therapies in inflammatory bowel disease

Shiva T Radhakrishnan  1   2 , James L Alexander  1   2 , Benjamin H Mullish  1   2 , Kate I Gallagher  2 , Nick Powell  1   2 , Lucy C Hicks  1   2 , Ailsa L Hart  2   3 , Jia V Li  2 , Julian R Marchesi  2 , Horace R T Williams  1   2
Affiliations

Systematic review: the association between the gut microbiota and medical therapies in inflammatory bowel disease

Shiva T Radhakrishnan et al. Aliment Pharmacol Ther. 2022 Jan.

Abstract

Background: The gut microbiota has been implicated in the pathogenesis of inflammatory bowel disease (IBD), with Faecalibacterium prausnitizii associated with protection, and certain genera (including Shigella and Escherichia) associated with adverse features. The variability of patient response to medical therapies in IBD is incompletely understood. Given the recognised contribution of the microbiota to treatment efficacy in other conditions, there may be interplay between the gut microbiota, IBD medical therapy and IBD phenotype.

Aims: To evaluate the bidirectional relationship between IBD medical therapies and the gut microbiota.

Methods: We conducted a systematic search of MEDLINE and EMBASE. All original studies analysing interactions between the gut microbiota and established IBD medical therapies were included.

Results: We screened 1296 records; 19 studies were eligible. There was heterogeneity in terms of sample analysis, treatment protocols, and outcome reporting. Increased baseline α-diversity was observed in responders versus non-responders treated with exclusive enteral nutrition (EEN), infliximab, ustekinumab or vedolizumab. Higher baseline Faecalibacterium predicted response to infliximab and ustekinumab. A post-treatment increase in Faecalibacterium prausnitzii was noted in responders to aminosalicylates, anti-TNF medications and ustekinumab; conversely, this species decreased in responders to EEN. Escherichia was a consistent marker of unfavourable drug response, and its presence in the gut mucosa correlated with inflammation in aminosalicylate-treated patients.

Conclusions: Both gut microbiota diversity and specific taxonomic features (including high abundance of Faecalibacterium) are associated with the efficacy of a range of IBD therapies. These findings hold promise for a potential role for the gut microbiota in explaining the heterogeneity of patient response to IBD treatments.

PubMed Disclaimer

References

REFERENCES

    1. Gasparetto M, Guariso G. Highlights in IBD epidemiology and its natural history in the paediatric age gastroenterology research and practice. Gastroenterol Res Pract. 2013;2013:1-12.
    1. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46-54.e42;quiz e30.
    1. Jones G-R, Lyons M, Plevris N, et al. IBD prevalence in Lothian, Scotland, derived by capture-recapture methodology. Gut. 2019;68:1953-1960.
    1. Zhang Y-Z, Li Y-Y. Inflammatory bowel disease: pathogenesis. World J Gastroenterol. 2014;20:91.
    1. Marchesi JR, Adams DH, Fava F, et al. The gut microbiota and host health: a new clinical frontier. Gut. 2016;65:330-339.

Publication types

Substances

LinkOut - more resources